Literature DB >> 10388792

Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?

M A Lee1, S Smith, J Palace, S Narayanan, N Silver, L Minicucci, M Filippi, D H Miller, D L Arnold, P M Matthews.   

Abstract

It is generally believed that most T2-weighted (T2) lesions in the central white matter of patients with multiple sclerosis begin with a variable period of T1-weighted (T1) gadolinium (Gd) enhancement and that T1 Gd-enhancing and T2 lesions represent stages of a single pathological process. Lesion probability maps can be used to test this hypothesis by providing a quantitative description of the spatial distribution of these two types of lesions across a patient population. The simplest prediction of this hypothesis would be that the spatial distributions of T1 Gd-enhancing and T2 lesions are identical. We generated T1 Gd-enhancing and T2 lesion probability maps from 19 patients with relapsing-remitting multiple sclerosis. There was a significantly higher probability (P = 0.001) for T2 lesions to be found in the central relative to the peripheral white matter (risk ratio 4.5), although the relative distribution of T1 Gd-enhancing lesions was not significantly different (P = 0.7) between central and peripheral white matter regions (risk ratio 0.6). Longitudinal data on the same population were used to demonstrate a similar distribution asymmetry between new T1 Gd-enhancing and new T2 lesions that developed over the course of 1 year. Alternative hypotheses to explain this observation were tested. We found no spatial difference in the likelihood of development of persistent T2 lesions following T1 Gd enhancement. The relative distribution of T1 Gd-enhancing lesions was shown to be independent of the dose of Gd contrast agent and the frequency of scanning. Our findings suggest that a proportion of the periventricular T2 lesion volume may arise from mechanisms other than those associated with early breakdown of the blood-brain barrier leading to T1 Gd enhancement.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10388792     DOI: 10.1093/brain/122.7.1261

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  15 in total

Review 1.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

2.  Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis.

Authors:  Yong Wang; Peng Sun; Qing Wang; Kathryn Trinkaus; Robert E Schmidt; Robert T Naismith; Anne H Cross; Sheng-Kwei Song
Journal:  Brain       Date:  2015-02-26       Impact factor: 13.501

3.  Hypoperfusion and T1-hypointense lesions in white matter in multiple sclerosis.

Authors:  Ponnada A Narayana; Yuxiang Zhou; Khader M Hasan; Sushmita Datta; Xiaojun Sun; Jerry S Wolinsky
Journal:  Mult Scler       Date:  2013-07-08       Impact factor: 6.312

4.  Lesion probability maps of white matter hyperintensities in elderly individuals: results of the Austrian stroke prevention study.

Authors:  Christian Enzinger; Stephen Smith; Franz Fazekas; Gunther Drevin; Stefan Ropele; Thomas Nichols; Timothy Behrens; Reinhold Schmidt; Paul M Matthews
Journal:  J Neurol       Date:  2006-04-10       Impact factor: 4.849

5.  Genetic correlations of brain lesion distribution in multiple sclerosis: an exploratory study.

Authors:  M H Sombekke; M M Vellinga; B M J Uitdehaag; F Barkhof; C H Polman; D Arteta; D Tejedor; A Martinez; J B A Crusius; A S Peña; J J G Geurts; H Vrenken
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-24       Impact factor: 3.825

Review 6.  Immunopathogenesis of the multiple sclerosis lesion.

Authors:  S Markovic-Plese; H F McFarland
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

7.  Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.

Authors:  Lucy Matthews; Rita Marasco; Mark Jenkinson; Wilhelm Küker; Sebastian Luppe; Maria Isabel Leite; Antonio Giorgio; Nicola De Stefano; Neil Robertson; Heidi Johansen-Berg; Nikos Evangelou; Jacqueline Palace
Journal:  Neurology       Date:  2013-03-13       Impact factor: 9.910

8.  Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis.

Authors:  Kerstin Bendfeldt; Jan Ole Blumhagen; Hanspeter Egger; Patrick Loetscher; Niklaus Denier; Pascal Kuster; Stefan Traud; Nicole Mueller-Lenke; Yvonne Naegelin; Achim Gass; Jochen Hirsch; Ludwig Kappos; Thomas E Nichols; Ernst-Wilhelm Radue; Stefan J Borgwardt
Journal:  Hum Brain Mapp       Date:  2010-10       Impact factor: 5.038

Review 9.  Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis.

Authors:  Ruth Geraldes; Margaret M Esiri; Gabriele C DeLuca; Jacqueline Palace
Journal:  Brain Pathol       Date:  2017-03-12       Impact factor: 6.508

10.  Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition.

Authors:  S C Manson; C Wegner; M Filippi; F Barkhof; C Beckmann; O Ciccarelli; N De Stefano; Christian Enzinger; F Fazekas; F Agosta; A Gass; J Hirsch; H Johansen-Berg; L Kappos; T Korteweg; C Polman; L Mancini; F Manfredonia; S Marino; D H Miller; X Montalban; J Palace; M Rocca; S Ropele; A Rovira; S Smith; A Thompson; J Thornton; T Yousry; J A Frank; P M Matthews
Journal:  Exp Brain Res       Date:  2008-01-31       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.